Researchers Solve 50-Year-Old Challenge in Making Cancer Drug
Scientists have overcome production barriers that have plagued doxorubicin manufacturing since the 1970s by engineering bacteria that generate 180% more of the critical chemotherapy drug than current methods achieve. The breakthrough addresses molecular bottlenecks that forced pharmaceutical companies to rely on expensive, multi-step processes despite treating over one million cancer patients annually with the medication. The advance could reshape how essential medicines get produced globally. Doxorubicin has been essential to the treatment of breast cancer, bladder cancer, lymphomas, and carcinomas since gaining approval five decades ago. However, bacteria that naturally synthesize the compound do so extremely inefficiently, creating supply constraints…
